BELITE BIO, INC — Investor Relations & Filings

Belite Bio is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for retinal degenerative eye diseases and metabolic conditions with significant unmet medical needs. The company's lead candidate, Tinlarebant (LBS-008), is a novel oral therapy designed to reduce the accumulation of ocular toxins by targeting Retinol Binding Protein 4 (RBP4). Tinlarebant is in late-stage clinical development for the treatment of Stargardt disease (STGD1) and Geographic Atrophy (GA), an advanced form of dry age-related macular degeneration. The drug has received multiple regulatory designations, including Orphan Drug, Rare Pediatric Disease, Breakthrough Therapy, and Fast Track in the U.S., as well as Orphan Drug designation in Europe and Sakigake designation in Japan.